Skip to main
NTHI

NTHI Stock Forecast & Price Target

NTHI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeOnc Technologies Hldgs is positioned for success with their innovative approach to CNS drug delivery, strong pipeline of potential treatments, and expansion plans. The company's collaborations with leading research institutions and promising clinical trial results provide confidence in their ability to obtain FDA approval and bring their drugs to market in the near future. Financially, their strong cash position and low burn rate indicate stability and potential for future growth.

Bears say

NeOnc Technologies Hldgs is a clinical-stage biopharmaceutical company with promising drug candidates that target central nervous system diseases. However, there are multiple risks associated with its products and the competitive landscape, as well as potential challenges with pricing and reimbursement. This, along with the company's relatively small size and limited pipeline, leads to a negative outlook on its stock. Additionally, the company's financials show an increase in bridge loan expenses and no changes in operating assets and liabilities, indicating potential financial challenges ahead.

NTHI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neonc Technologies Holdings Inc (NTHI) Forecast

Analysts have given NTHI a Strong Buy based on their latest research and market trends.

According to 3 analysts, NTHI has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neonc Technologies Holdings Inc (NTHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.